secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001093557-26-000038
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kevin Sayer returns as DexCom Executive Chairman on Mar 2 with new comp terms
-----------------------------------------------------------------------------

- Kevin Sayer returns from temporary leave effective March 2, 2026, resuming Executive Chairman role.
- New letter agreement provides annual base salary of $610,000; no annual bonus.
- RSU grant of $2,350,000 to be awarded on March 8, 2026, vesting in full on March 8, 2027.
- Former equity awards continue to vest; Sayer no longer eligible for Company's severance plan.
- Mark Foletta resumes duties as Lead Independent Director upon Sayer's return.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355726000038/0001093557-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355726000038/dxcm-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001093557-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer